Jon B. Dubrow
Subscribe to Jon B. Dubrow's PostsJon Dubrow is co-head of McDermott’s Antitrust Mergers Focus Group and is a strategic advisor serving clients across a host of inter-related antitrust issues, including mergers and acquisitions (M&A) transactions / merger clearance, counseling and litigation. Jon leads the defense of mergers, acquisitions and joint ventures before the Department of Justice, the Federal Trade Commission and other international competition authorities. He also regularly assists third parties whose interests are adversely affected by proposed transactions. Jon also is experienced in antitrust litigation. He provides counseling on distribution issues, contracting arrangements and a wide variety of other competition-related matters. Read Jon Dubrow's full bio.
Understanding How the New HSR Regime Impacts Your Business
By Jon B. Dubrow, Gregory E. Heltzer, Lisa P. Rumin, Ryan Tisch, Timothy (Ty) Carson and Reese Poncia on Nov 5, 2024
Posted In FTC Developments, Mergers & Acquisitions
During a recent webinar, Jon Dubrow, Greg Heltzer, Lisa Rumin, and Ryan Tisch provided a comprehensive introduction to the new Hart-Scott-Rodino (HSR) rules and their impact on the US premerger notification filing process. The program concluded with a Q&A moderated by Reese Poncia and featuring Ty Carson, a former Federal Trade Commission Premerger Notification Office lawyer, who shared his insider’s perspective from six years...
Continue Reading
New Premerger Notification Regime to Fundamentally Change M&A Strategy
By Jon B. Dubrow, Raymond A. Jacobsen, Jr., Lisa P. Rumin, Ryan Tisch, Noah Feldman Greene, Graham Hyman and Reese Poncia on Oct 16, 2024
Posted In FTC Developments, Mergers & Acquisitions
On October 10, 2024, the Federal Trade Commission issued new final rules governing the US premerger notification filing process. These rules – the first major overhaul to the Hart-Scott-Rodino (HSR) filing form in the nearly 50-year history of the HSR Act – will fundamentally alter the premerger notification process. While the rules omit some of...
Continue Reading
States Want in on the Merger Review Fun
By Jon B. Dubrow, Elai Katz and Betty Zhang on Aug 8, 2024
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Joint Ventures/Competitor Collaboration, Mergers & Acquisitions
WHAT HAPPENED While they have long taken a back seat to federal merger reviews, US states are becoming increasingly involved in merger reviews, including potentially requiring premerger notifications on a broad scale. On July 24, 2024, the Uniform Law Commission adopted its Uniform Antitrust Pre-Merger Notification Act (Model Act) as model legislation for states to...
Continue Reading
Antitrust M&A Snapshot | Q2 2024
By Glenna Siegel, Mary Hecht, Jon B. Dubrow, Joel R. Grosberg, Stéphane Dionnet, Graham Hyman and Max Küttner on Jul 25, 2024
Posted In Cartel Enforcement, DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Topics covered in this edition: UNITED STATES US agencies are increasingly scrutinizing consummated mergers from years past, including Live Nation’s purchase of Ticketmaster and Meta’s acquisitions of Instagram and WhatsApp. Reports indicate that, over the past three years, companies have abandoned 37 deals in the face of Federal Trade Commission pressure. Merger activity in oil...
Continue Reading
Antitrust M&A Snapshot | Q1 2024
By Reese Poncia, Julian Rößler-Weis, Jon B. Dubrow, Joel R. Grosberg, Stéphane Dionnet, Graham Hyman and Max Küttner on May 2, 2024
Posted In Cartel Enforcement, DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Topics covered in this edition: The Federal Trade Commission (FTC) and US Department of Justice have begun implementing the 2023 Merger Guidelines in their enforcement actions During a virtual workshop, the FTC highlighted its focus on private equity (PE) acquisitions of healthcare service providers and expressed concerns about PE in healthcare Artificial intelligence’s antitrust implications...
Continue Reading
Antitrust M&A Snapshot | Q4 2023
By Claire Danberg, Emilia Bonine, Jon B. Dubrow, Joel R. Grosberg, Stéphane Dionnet, Matt Evola and Max Küttner on Feb 14, 2024
Posted In DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Topics covered in this edition: New Merger Guidelines Released FTC Focused on Pharmaceutical Companies FTC Targets “Moat-Building” Mergers Fifth Circuit Fuels FTC’s Vertical Mergers Agenda FTC Losing Streak Reverses During the Fourth Quarter Ex post Review in the Merger Control Sphere Occurring More and More Frequently Access the full issue.
Continue Reading
The Fix Is In – Key Learnings From Recent Vertical Merger Challenges
By Jon B. Dubrow, Stephen Wu, Matt Evola and Bailey K. Sanders on Feb 9, 2024
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Vertical mergers are inherently more difficult for the government to litigate than horizonal mergers. After not litigating a vertical merger case since the 1970s, the Federal Trade Commission and the US Department of Justice have recently tried several matters. In this Westlaw Today article, Jon Dubrow, Stephen Wu, Matt Evola and Bailey Sanders discuss key...
Continue Reading
New FTC, DOJ Merger Guidelines Create Challenges and Opportunities
By Jon B. Dubrow, Raymond A. Jacobsen, Jr., Ryan Tisch and Joel R. Grosberg on Dec 21, 2023
Posted In DOJ Developments, FTC Developments, Mergers & Acquisitions
The US Federal Trade Commission (FTC) and US Department of Justice Antitrust Division (DOJ) issued their updated Merger Guidelines on December 18, 2023. These guidelines represent a significantly more enforcement-oriented approach than the prior guidelines, and they largely follow the contours of draft guidelines released in July 2023. Companies should be aware of the Merger Guidelines...
Continue Reading
Antitrust M&A Snapshot | Q2 2023
By Graham Hyman, Mary Hecht, Jon B. Dubrow, Joel R. Grosberg, Stéphane Dionnet, Matt Evola and Max Küttner on Jul 31, 2023
Posted In DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Topics covered in this edition: FTC Unveils Proposal Detailing Significant Changes to Hart-Scott-Rodino Act Merger Notifications Assa Abloy Settlement Raises Questions on Litigating the Fix and DOJ Consent Decrees Pharmaceutical Industry Remains in Regulators’ Crosshairs “Whole of Government” Competition Mandate Can Impact Deals the FTC and DOJ Do Not Challenge FTC’s Constitutionality Comes Under Fire—Again...
Continue Reading
Proposed Merger Guidelines Outline Fundamental Change of Approach to Merger Investigation and Enforcement
By Nicole Castle, Jon B. Dubrow, Noah Feldman Greene, Gregory E. Heltzer, Joel R. Grosberg, Raymond A. Jacobsen, Jr., Lisa P. Rumin, Ryan Tisch and Stephen Wu on Jul 25, 2023
Posted In DOJ Developments, FTC Developments, Mergers & Acquisitions
Mergers and acquisitions will continue to face strong headwinds at the Federal Trade Commission and the US Department of Justice under new proposed Merger Guidelines released on July 19, 2023. The Proposed Guidelines embody the antitrust agencies’ aggressive posture toward merger enforcement under the Biden administration. This On the Subject highlights the most significant changes...
Continue Reading
